1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Opioid 'Data Warehouse' Is Part Of US FDA's New Controlled Substances Program

 
• By Derrick Gingery

CDER-based program lead by Marta Sokolowska will also handle benzodiazepine and stimulants activities and consult on relevant application assessments.

An ampoule Opioid next to it is a note written in English Opioid epidemic. All around, many tablets and syringes are scattered.
The FDA's new opioid data warehouse, intended to collect data related to the crisis and inform regulatory change, also will come under the CSP purview. • Source: Shutterstock

Controlled substance activities now are under one umbrella at the US Food and Drug Administration’s Center for Drug Evaluation and Research, a promotion of sorts as the agency’s response to the opioid crisis grows.

A new Controlled Substances Program (CSP) has been established at CDER, which will house the Controlled Substances Staff and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Kennedy Maintains mRNA Negativity Even When Couched As Trump Success

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary's Sept. 4 appearance at the Senate Finance Committee also revealed more Republicans are souring on his vaccine policies, although most still support him.

US FDA Compounding Advisory Panel Hit Hardest By Recent Purges

 
• By Sarah Karlin-Smith

A Pink Sheet review found 10 FDA advisory panel members recently pulled off committees despite having time left in their appointed terms.

Offit’s VRBPAC Departure Raises Questions About Another HHS Panel Revamp

 
• By Sarah Karlin-Smith and Derrick Gingery

Offit, an outspoken critic of the Trump Administration's vaccine agenda, is no longer slated to serve two more years on the FDA's Vaccines and Related Biologics Products Advisory Committee.

New US FDA AI Councils Will Focus On Internal, External Policy

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

More from Agency Leadership

Brazil & Mexico Bet On Regulatory Reliance To Improve Pharmacovigilance & Access To Medicines

 
• By Francesca Bruce

Two of Latin America’s biggest regulators have signed a memorandum of understanding to deepen cooperation and improve access to medicines.

New US FDA AI Councils Will Focus On Internal, External Policy

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

EMA Learns Hard Lessons From US-Inspired Streamlining Pilot

 
• By Vibha Sharma

The European Medicines Agency’s ongoing pilot to streamline drug reviews by allowing companies to voluntarily pre-fill factual data in assessment report templates appears to add significant workload for industry, without delivering clear value to regulators.